Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 501–600 of 2,039
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Sinha, B., & Ghosal, S. (2025) · Obesity · doi:10.1002/oby.24360 · Cited by 31
“Our efficacy findings align with prior meta-analyses, where GLP-1RAs achieved significant weight loss ( − 6 to − 10 kg) compared to placebo, and dual agonists showed superior reductions ( − 10 to − 12 kg) in T2DM cohorts [25, 26].”
Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Fanshier, A. V., Crews, B. K., Garrett, M. C., & Johnson, J. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0060 · Cited by 22
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
“While no significant improvement between NNC0090-2746 and liraglutide in terms of reduction of hyperglycaemia and weight loss was observed in patients with T2D [192], tirzepatide showed greater benefits on both these endpoints compared to semaglutide [193], thus becoming the most effective anti-obesity drug currently…”
BackgroundGPCR-mediated effects of fatty acids and bile acids on glucose homeostasis
Oteng, A., & Liu, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1206063 · Cited by 25
Boye, K. S., Thieu, V. T., Sapin, H., Lee, C. J., Landó, L. F., Brown, K. E., Bray, R., Wiese, R. J., Patel, H., Rodríguez, Á., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01451-z · Cited by 21
Self-citationTreating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Gurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
Kelly, M. S., Scopelliti, E. M., Goodson, K. E., Lo, C. M. A., Nguyen, H. X., & Simon, B. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15934 · Cited by 21
Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
Iwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Yamasaki, Y., Nogami, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15972 · Cited by 22
Effects of Tirzepatide in Type 2 Diabetes
Aminorroaya, A., Oikonomou, E. K., Biswas, D., Jastreboff, A. M., & Khera, R. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.516 · Cited by 22
Safwan, M., Bourgleh, M. S., Alotaibi, S. A., Alotaibi, E. A., Al-Ruqi, A., & Raeya, F. E. (2025) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2025.129 · Cited by 77
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16508 · Cited by 27
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Sattar, N. A., García‐Pérez, L., Rodríguez, Á., Kapoor, R., Stefański, A., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16549 · Cited by 28
Souto, M., Gonçalves, T. C., & Cotter, J. B. (2025) · Nutrients · doi:10.3390/nu17142310 · Cited by 26
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 31
New Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
He, F., Chen, W., Xu, W., Liu, D., Xiao, Z., Tang, Y., Lin, Z., Liao, Y., Bin, J., Chen, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14908 · Cited by 21
“Tirzepatide (a dual glucose-dependent insulinotropic polypeptide-GLP-1 RA) and semaglutide (a selective GLP-1 RA) reduce glycated haemoglobin levels and body weight in patients with T2DM when injected subcutaneously once-a-week.(39) Semaglutide has also been developed as a once-a-day oral administration.”
BackgroundObesity and diabetes: the final frontier
Rendell, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168643 · Cited by 23
Zhang, C., Yang, X., Meng, X., Wu, L., Liu, X., Gao, J., Liu, S., Wu, J., Huang, D., Wang, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02003 · Cited by 19
Metabolism-based approaches for autosomal dominant polycystic kidney disease
Bakaj, I., & Pocai, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1126055 · Cited by 22
“One attractive feature of new generation GLP-1 analogues is the propound weight loss (>10%) achieved in obese and diabetic patients (Frías et al., 2021).”
BackgroundRecent Advances in Formulations for Long-Acting Delivery of Therapeutic Peptides
Zangabad, P. S., Abousalman‐Rezvani, Z., Tong, Z., Esser, L., Vasani, R. B., & Voelcker, N. H. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00193 · Cited by 22
Rohani, P., Malekpour Alamdari, N., Bagheri, S. E., Hekmatdoost, A., & Sohouli, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230206 · Cited by 18
Rasouli, N., Younes, N., Ghosh, A., Albu, J., Cohen, R. M., DeFronzo, R. A., Diaz, E., Kassem, L. S., Luchsinger, J. A., McGill, J. B., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1070 · Cited by 27
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
“…mg tirze-patide in the SURPASS-2 trials carried out overseas produced a signi fi cant reduction in bodyweight compared with the GLP-1 receptor agonist, semaglutide 1.0 mg 51 ; Thus, tirzepatide is deemed the most effective medication in bodyweight reduction among existing antidiabetic medications.”
MethodInfluentialBouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
“…10, and 15 mg tirzepatide in SURPASS-2 trials conducted overseas produced a significant reduction in body weight compared to GLP-1 receptor agonists samaglutide 1.0 mg [51]; Thus, tirzepatide is deemed the most effective medication in body weight reduction among existing antidiabetic medications.”
InfluentialRubinić, I., Kurtov, M., & Likić, R. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1243 · Cited by 27
“27,43,44,45,46 This review will shift its focus toward exploring alternative gut peptides with the potential to influence appetite and food intake offering effective avenues for treating obesity.”
BackgroundTirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
Frías, J. P., Landó, L. F., & Brown, K. E. (2022) · PubMed · doi:10.1056/nejmc2114590 · Cited by 16
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1513641 · Cited by 17
An updated patent review of GLP-1 receptor agonists (2020-present)
Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2274905 · Cited by 17
A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide
Chan, L. J., Kaur, M., & Kaffenberger, B. H. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.02.023 · Cited by 22
Holistic and Personalized Strategies for Managing in Elderly Type 2 Diabetes Patients
Yun, J., Kim, K., Ahn, Y., Han, K., & Ko, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0310 · Cited by 29
“With regard to GLP-1 RAs, clinical research reports indicate that 40% of patients initially experience nausea, vomiting, and diarrhea, and some may experience severe gastrointestinal disorders, making them a less preferred treatment for frail elderly patients [67].”
BackgroundGLP-1 receptor agonists in the context of cancer: the road ahead
Miousse, I. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00245.2025 · Cited by 23
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 27
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
de Bray, A., Roberts, A. G., Armour, S. L., Tong, J., Huhn, C., Gatin‐Fraudet, B., Roßmann, K., Shilleh, A. H., Jiang, W., Burgos, N. S. F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01342-6 · Cited by 21
“Specific antibodies exist for GLP1R, but no reliable commercial antibody exists yet for the detection of GIPR in primary cells and tissues 13 .”
Patoulias, D., Doumas, M. N., & Papadopoulos, C. E. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.03.042 · Cited by 18
Shifting Tides Offer New Hope For Obesity
Rosen, C. J., & Ingelfinger, J. R. (2022) · New England Journal of Medicine · doi:10.1056/nejme2206939 · Cited by 17
Incretin based therapy and pancreatic cancer: Realising the reality
Suryadevara, V., Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i25.2881 · Cited by 23
Yu, Y., Hu, G., Yin, S., Yang, X., Zhou, M., & Jian, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.990182 · Cited by 17
“Notably, the results of the studies (24, 28) showed that GI AEs were dose-independent, with the exception of Frias2018 (29) which supported a dose-dependent GI AEs for TZP, a discrepancy that may be related to the course of treatment.”
BackgroundResultInfluentialMucosal and hormonal adaptations after Roux-en-Y gastric bypass
Feris, F., MCRAE, A. N., Kellogg, T. A., McKenzie, T. J., Ghanem, O. M., & Acosta, A. J. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.020 · Cited by 22
Lee, W.-L., Wang, P., Yang, S., Liu, C., Chang, W.-H., & Lee, F. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000831 · Cited by 22
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., & Negm, W. A. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01239-4 · Cited by 19
Larsen, A. T., Melander, S. A., Sonne, N., BREDTOFT, E.-M., Al-Rubai, M., Karsdal, M. A., & Henriksen, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114969 · Cited by 17
Updates on dyslipidemia in patients with diabetes
Ide, S., Maezawa, Y., & Yokote, K. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14042 · Cited by 24
Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
Karrar, H. R., Nouh, M. I., Nouh, Y. I., Nooh, M. I., Alhindi, A. S. K., Hemeq, Y. H., Aljameeli, A. M. S., Aljuaid, J. A., Alzahrani, S. J., Alsatami, A. A., et al. (2023) · Cureus · doi:10.7759/cureus.46091 · Cited by 31
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Pinto, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1952 · Cited by 20
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
GLP-1/GIP/glucagon receptor triagonism gets its try in humans
Finan, B., & Douros, J. D. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.010 · Cited by 17
Bucheit, J. D., Ayers, J., Pamulapati, L. G., Browning, A., & Sisson, E. M. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001299 · Cited by 20
Soresi, M., & Giannitrapani, L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i30.3541 · Cited by 20
Wen, J., Syed, B., Nadora, D., How‐Volkman, C., Bernstein, E., Truong, A., Akhtar, M., Razick, A., Puglisi, J., & Frezza, E. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70045 · Cited by 17
“There were two RCTs [9, 10] and two retrospective observational studies [5, 11].”
InfluentialJabbour, S. A., Paik, J. S., Aleppo, G., Sharma, P., Valderas, E. G., & Benneyworth, B. D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.005 · Cited by 25
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Hankosky, E. R., He, X., Malik, R., Brumm, J. F., Wang, F., Niemeyer, A., Zhang, X. M., & Garvey, W. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16401 · Cited by 24
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 28
Eisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 48
Frías, J. P. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2184796 · Cited by 19
“5% and 2) body weight reduction ≥10% and 3) no clinically significant hypoglycemia (glucose <54 mg/dL or severe hypoglycemia) was achieved by 32%, 51%, and 60% of patients treated with tirzepatide 5 mg, 10 mg, and 15 mg, respectively, and 22% of semaglutide-treated patients at week 40 (Figure 5) [24].”
BackgroundInfluentialSelf-citationTen reasons gastroenterologists and hepatologists should be treating obesity
Camilleri, M., & El-Omar, E. M. (2023) · Gut · doi:10.1136/gutjnl-2023-329639 · Cited by 18
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Kubota, M., Yamamoto, K., & Yoshiyama, S. (2023) · Cureus · doi:10.7759/cureus.46490 · Cited by 16
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
“The comparison of tirzepatide 5, 10, or 15 mg with semaglutide 1.0 mg in subjects with T2D showed similar incidence of gastrointestinal AE [21].”
InfluentialTirzepatide-induced ketoacidosis in non-diabetic patients
Iqbal, P. M. R., Maadarani, O. S., & Bitar, Z. I. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004357 · Cited by 18
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Depending on the dose (5, 10, or 15 mg once-weekly; QW), participants achieved a reduction in HbA1c of up to 2.59%, with placebo-corrected body weight loss of 7 – 14,5% after 40 – 52 wks of treatment [18 – 22].”
InfluentialMetabolic disorders in prediabetes: From mechanisms to therapeutic management
Ping, W.-X., Hu, S., Su, J., & Ouyang, S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.361 · Cited by 25
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Suzuki, T., Sato, T., Tanaka, M., Endo, K., Nakata, K., Ogawa, T., Hosaka, I., Akiyama, Y., Umetsu, A., & Furuhashi, M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108779 · Cited by 18
Chae, Y., Kwon, S., Nam, J. H., Kang, E., Im, J., Kim, H.-J., & Lee, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2363838 · Cited by 18
Popovic, D. S., Patoulias, D., Koufakis, T., Stavropoulos, K., Karakasis, P., Ruža, I., Παπάνας, Ν., Rizzo, M., & Doumas, M. N. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108800 · Cited by 17
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
A Rare Case of Tirzepatide-Induced Hepatotoxicity
Sohal, A., Casanova, L., & Kowdley, K. V. (2024) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001484 · Cited by 20
Mahar, M. U., Mahmud, O., Ahmed, S., Qureshi, S. A., Kakar, W. G., & Fatima, S. S. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24008 · Cited by 31
Glycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Intestinal Enteroendocrine Cell Signaling: Retinol-binding Protein 2 and Retinoid Actions
Calderon, R. M., Smith, C. A., Miedzybrodzka, E. L., Silvaroli, J. A., Golczak, M., Gribble, F. M., Reimann, F. M., & Blaner, W. S. (2022) · Endocrinology · doi:10.1210/endocr/bqac064 · Cited by 15
Xu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Numerous RCTs have also reported that tirzepatide effectively lowers BP [159 , 162 , 164 ].”
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
Jensen, A. B., Machado, U., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., & Bilz, S. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01913-4 · Cited by 21
“Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP1-RA, has shown promising effects on weight reduction [25, 26].”
Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution
Hamley, I. W., de Mello, L. R., Castelletto, V., Zinn, T., Cowieson, N. P., Seitsonen, J. J. T., & Bizien, T. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00342 · Cited by 16
Masuda, Y., Ohbayashi, K., & Iwasaki, Y. (2025) · Diabetology International · doi:10.1007/s13340-025-00819-9 · Cited by 17
Mesinovic, J., Hurst, C., Leung, G. K. W., Ryan, J. R., Daly, R. M., & Scott, D. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09968-3 · Cited by 26
“…[132] and SURMOUNT-1 [130] could be attributed to medication differences or adherence to lifestyle counselling provided in the trials (e.g., ≥ 150 min/week physical activity and hypocaloric diets with ~ 20% protein intake); lean mass data has not been reported in head-to-head trials [134, 135].”
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Borner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1589 · Cited by 21
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“In the SURPASS-2 trial (NCT03987919), tirzepatide outperformed semaglutide 1.0 mg in both HbA1c and weight loss [56 ].”
InfluentialGLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
Kumar, V. (2025) · Open Biology · doi:10.1098/rsob.240303 · Cited by 18
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, A. A., Razick, D., Karabala, M., & Frezza, E. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104213 · Cited by 20
Chang, Y., Chi, K., Song, J., & Lin, H.-M. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.07.010 · Cited by 18
Tian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.